Conexeu Sciences (CNXU) vs Kazia Therapeutics (KZIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Conexeu Sciences is the larger company by market cap ($109.7 million vs $102.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNXU | KZIA |
|---|---|---|
| Share price | $3.89 | $8.93 |
| Market cap | $109.72M | $102.04M |
| 1-day change | +12.75% | +1.25% |
| YTD return | — | +29.61% |
| 1-year return | — | +24.37% |
| 5-year return | — | -98.30% |
| EPS (TTM) | $-0.61 | $-6.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.79 | $17.40 |
| 52-week low | $3.05 | $4.86 |
| Distance from 52-week high | -79.30% | -48.68% |
| Analyst consensus | none | none |
| Avg. price target upside | +414.14% | +216.46% |
| Average volume | 211.83K | 260.58K |
| Shares outstanding | 28.21M | 11.43M |
| Employees | — | 6 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Conexeu Sciences
CNXU stock →Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair.
Health Care · Industrial Specialties
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
CNXU vs KZIA FAQ
Which is bigger, Conexeu Sciences or Kazia Therapeutics?
Conexeu Sciences (CNXU) is larger, with a market capitalization of $109.72M compared with $102.04M for Kazia Therapeutics (KZIA).
Are Conexeu Sciences and Kazia Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Conexeu Sciences and Biotechnology: Pharmaceutical Preparations for Kazia Therapeutics.